Core Insights - OS Therapies has received positive feedback from the UK's MHRA regarding its OST-HER2 application for the prevention or delay of recurrent pulmonary metastatic osteosarcoma [1][2] - The company has initiated the regulatory process in Europe and plans to synchronize its application with the FDA's Accelerated Approval Program through Project Orbis [1][2][4] - OST-HER2 has shown statistically significant benefits in a Phase 2b clinical trial, with a focus on improving 12-month event-free survival rates [5] Regulatory Developments - The company held a successful Scientific Advice Meeting with the MHRA and submitted an Innovative Licensing and Access Pathway (ILAP) application [1][2] - MHRA recommended applying for Project Orbis to align the UK and US regulatory review processes [4] - A European Medicines Agency rapporteur has scheduled a Scientific Advice Meeting for October 2025 [4] Product Information - OST-HER2 is an immunotherapy targeting the HER2 protein, leveraging the immune-stimulatory effects of Listeria bacteria [3] - The product has received Rare Pediatric Disease Designation, Fast-Track, and Orphan Drug designations from the FDA and EMA [3] - The company anticipates submitting a Biologics Licensing Application (BLA) to the FDA in 2025, which could lead to a Priority Review Voucher [5] Future Developments - OS Therapies is advancing its next-generation Antibody Drug Conjugate (ADC) platform, known as tunable ADC (tADC), which utilizes proprietary technology for enhanced drug delivery [6]

Group 1 - The article reports significant declines in the stock prices of several Chinese concept stocks, with the largest drop being 27.78% for LZMH (联掌科技控股) [1] - Other notable declines include PAVS (幸福来) down 20.94%, ORIS (闽东红) down 18.49%, EHGO (君长数码) down 17.88%, and OST (奥斯汀科技集团) down 17.29% [1] - The trading volumes for these stocks vary, with LZMH having a trading volume of 2.4457 million and PAVS at 25,300, indicating varying levels of investor interest [1]

7月28日，奥斯汀科技于2025-08-05合股,25合1(预案)。 资料显示，奥斯汀科技集团有限公司是中国显示模块和偏光片的供应商。 该公司根据客户的规格设计, 开发和制造各种尺寸和定制尺寸的TFT-LCD模块。 它们的显示模块主要用于消费电子,户外LCD显示器 和汽车显示器。 该公司还制造用于TFT-LCD显示模块的偏光片,并且正在开发用于OLED显示面板的偏 光片。 本文源自：金融界 作者：行情君 8月5日，奥斯汀科技(OST)开盘上涨3.51%，截至21:30，报2.07美元/股，成交4.18万美元，总市值2.76亿 美元。 财务数据显示，截至2025年03月31日，奥斯汀科技收入总额2084.31万美元，同比增长39.2%；归母净利 润-517.94万美元，同比减少11.6%。 大事提醒： ...

In conjunction with the Reverse Share Split, the Company also amended its Memorandum of Association to proportionately reduce the number of authorized shares for issuance and to adjust the par value of the post- reverse share split ordinary shares to $0.025 per share. Nanjing, China, July 28, 2025 (GLOBE NEWSWIRE) -- Ostin Technology Group Co., Ltd. ("the Company") (NASDAQ:OST), a leading supplier of display modules and polarizers based in China, today announced that it has resolved to effect a reverse shar ...

Core Viewpoint - Univest Securities, LLC has successfully closed a registered direct offering for Ostin Technology Group Co., Ltd., raising approximately $5 million through the sale of 41,666,667 Class A ordinary shares at a price of $0.12 per share [1][2][3]. Group 1: Offering Details - The offering involved a single institutional investor purchasing an aggregate of 41,666,667 Class A ordinary shares or pre-funded warrants at a purchase price of $0.12 per share [2]. - The gross proceeds from this offering amounted to approximately $5 million [3]. - The offering was conducted under a shelf registration statement on Form F-3, which was declared effective by the SEC on May 28, 2024 [4]. Group 2: Company Background - Ostin Technology Group Co., Ltd. is a supplier of display modules and polarizers based in China, founded in 2010 [7]. - The company specializes in designing, developing, and manufacturing TFT-LCD display modules used in consumer electronics, outdoor LCD displays, and automotive displays [7]. - Ostin also manufactures polarizers that are utilized in its TFT-LCD display modules [7]. Group 3: Univest Securities Overview - Univest Securities, LLC is a full-service investment bank and securities broker-dealer firm based in New York, registered with FINRA since 1994 [6]. - The firm has raised over $1.3 billion in capital for issuers globally since 2019 and has completed approximately 100 transactions across various industries [6].

Group 1 - The Company, Ostin Technology Group Co., Ltd., has entered into a definitive agreement for the purchase and sale of 41,666,667 Class A ordinary shares at a price of $0.12 per share, resulting in expected gross proceeds of approximately $5 million [1][2]. - The transaction is anticipated to close on or about July 1, 2025, pending customary closing conditions [2]. - The offering is conducted under a shelf registration statement previously filed with the SEC, which was declared effective on May 28, 2024 [3]. Group 2 - Ostin Technology Group, founded in 2010, specializes in the design, development, and manufacturing of TFT-LCD display modules and polarizers, primarily for consumer electronics, outdoor LCD displays, and automotive displays [5].

Core Viewpoint - Ostin Technology Group Co., Ltd. has addressed recent abnormal stock price fluctuations, stating that there are no undisclosed material matters and cautioning investors to rely on official statements and filings with the U.S. Securities and Exchange Commission [1]. Company Overview - Ostin Technology Group Co., Ltd. was founded in 2010 and is a supplier of display modules and polarizers in China [2]. - The company designs, develops, and manufactures TFT-LCD display modules in various sizes, primarily for consumer electronics, outdoor LCD displays, and automotive displays [2]. - Additionally, Ostin Technology produces polarizers used in TFT-LCD display modules [2]. Investor Communication - The company has indicated that it does not intend to make further statements regarding the recent stock price fluctuations [1]. - Investors are advised to refer to the company's official communications for accurate information [1].

Market Overview - US stock indices experienced a significant rise for the third consecutive trading day, with the Dow Jones up 486.83 points (1.23%), Nasdaq up 457.99 points (2.74%), and S&P 500 up 108.91 points (2.03%) on April 24 [1] Technology Sector Performance - Major tech stocks saw substantial gains, with Tesla, Amazon, and Microsoft rising over 3%, while Google and Meta increased by more than 2%, and Apple rose nearly 2% [2] - The semiconductor sector led the gains, with Micron Technology and Broadcom up over 6%, Intel and AMD rising over 4%, and Nvidia increasing by more than 3% [2] - Nvidia's market capitalization increased by $90.8 billion (approximately ¥661.8 billion) in one night [2] Company Earnings Reports - Alphabet (Google's parent company) reported Q1 revenue of $90.23 billion, a 12% year-over-year increase, exceeding the expected $89.1 billion. Earnings per share were $2.81, up from $1.89 a year ago, and also above the forecast of $2.01. The operating profit was $30.61 billion, a 20% increase year-over-year, surpassing the expected $28.86 billion. The board authorized a stock buyback of up to $70 billion [6] - Intel reported Q1 revenue of $12.67 billion, a slight decline of 0.4% year-over-year, but above the expected $12.31 billion. Adjusted earnings per share were $0.13, down from $0.18 a year ago, but above the forecast of $0.01. The data center and AI revenue was $4.13 billion, exceeding the analyst expectation of $2.96 billion. Intel projected Q2 revenue between $11.2 billion and $12.4 billion, below the market estimate of $12.88 billion. The company reduced its total capital expenditure target for 2025 from $20 billion to $18 billion, leading to a post-earnings drop of over 7% in its stock [7] Chinese Stocks Performance - The Nasdaq Golden Dragon China Index rose by 0.68%, with notable gains in popular Chinese stocks such as NIO and Futu Holdings, which increased by over 6%, and Pinduoduo, Baidu, NetEase, and Bilibili rising over 2%. Xpeng Motors surged by 39.41%, and ZYBT rose by 34.91% [7][8] Commodity Market - International precious metals futures saw a general increase, with COMEX gold futures rising by 2.04% to $3,361.30 per ounce, and WTI crude oil futures up by 0.84% to $62.79 per barrel [9]

Core Viewpoint - Ostin Technology Group Co., Ltd. has entered into a securities purchase agreement to sell Class A ordinary shares and associated warrants, aiming to raise approximately $5.0 million in gross proceeds from the offering [3]. Group 1: Securities Offering Details - The company is offering 9,090,908 Class A ordinary shares at a combined price of $0.55 per share, along with two associated warrants for each share [1]. - Each warrant allows the purchase of one Class A ordinary share at an exercise price of $0.8, which will be immediately exercisable and will expire two years from the issuance date [2]. - The offering was closed on April 15, 2025, and the gross proceeds are expected to be approximately $5.0 million before deducting offering expenses [3]. Group 2: Regulatory Compliance - The securities offered are issued under a shelf registration statement on Form F-3, which was declared effective by the U.S. Securities and Exchange Commission on May 28, 2024 [4]. - A prospectus supplement related to the offering will be filed with the SEC, and copies will be available on the SEC's website [4]. Group 3: Company Overview - Ostin Technology Group, founded in 2010, specializes in the design, development, and manufacturing of TFT-LCD display modules and polarizers, primarily for consumer electronics, outdoor displays, and automotive applications [6].

Core Viewpoint - OS Therapies has announced positive data for its treatment OST-HER2 in dogs with unresected osteosarcoma, indicating potential for use as a frontline therapy in humans, aiming to prevent or delay limb amputation and reduce the need for chemotherapy [2][4][8] Group 1: Treatment Efficacy - OST-HER2 combined with palliative radiation showed clinical and radiographic arrest of primary tumors in dogs, leading to prolonged time to metastasis without surgery or chemotherapy [2][4] - The treatment demonstrated a significant improvement in overall survival, with 5 out of 15 dogs surviving over 500 days [6] - Positive data published in "Molecular Therapy" correlates immune responses to OST-HER2 with prevention of metastasis and long-term survival benefits [3][6] Group 2: Safety and Tolerability - Treatment with OST-HER2 was found to be safe and well tolerated in both studies conducted [4][6] Group 3: Future Plans and Approvals - The company plans to submit data to the USDA for conditional approval of the new manufacturing process for OST-HER2, aiming for sales to begin in 2025 [7] - A pivotal clinical study is planned to gain full approval by 2026 [7] - The company is focused on obtaining Accelerated Approval for OST-HER2 in recurrent, fully resected, lung metastatic human osteosarcoma by the end of 2025 [8] Group 4: Company Background - OS Therapies is a clinical-stage oncology company specializing in treatments for osteosarcoma and other solid tumors, with OST-HER2 as its lead asset [9] - The company has received various designations from the FDA, including Rare Pediatric Disease Designation and Fast-Track status [9] - OST-HER2 has shown statistically significant benefits in previous clinical trials for lung metastatic osteosarcoma [9]